Background: The aim of this study was to evaluate the effect of ß-Dmannuronic
acid (M2000) on related miRNAs to dendritic cells (DCs) differentiation.
DC-based immunosuppressive drugs can suppress the progression of autoimmune
diseases, however, their notable side effects in increasing the risk of infectious diseases
and cancers should be considered. The β-D-mannuronic acid, as a novel non-steroidal
anti-inflammatory agent, has been tested in various experimental models.
Method: The effect of M2000 on expression of miRNA-155 and miRNA-221 was
examined. To investigate how M2000 affects differentiation of human dendritic DCs in a
defined inflammatory environment, human peripheral blood mononuclear cells were
isolated from healthy blood and the monocytes were purified using anti-CD14
microbeads. The so isolated monocytes were subsequently incubated in the presence of
M2000 in two different doses (3 and 6 mMol/well) adding granulocyte-macrophage
colony-stimulating factor (GM-CSF) and interleukin-4 for inducing monocytes to
immature DC and lipopolysaccharide for running DC differentiation. The expression of
miRNA-155 and miRNA-221 were examined with Real Time PCR.
Results: The results demonstrate that M2000 has no significant side effect on expression
of miR-155 and miR-221 in both immature DC and mature DC process in vitro.
Conclusion: Our findings show that β-D-mannuronic acid is a safe agent which has no
adverse effect on regulatory miRNA-155 and miRNA-221 in dendritic cells.